Bank Of New York Mellon Corp Inhibikase Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.54 - $0.91 $21,063 - $35,496	39,007 New	39,007 $25.7 Million
Q4 2022 Feb 14, 2023	BUY	$0.45 - $0.78 $17,553 - $30,425	39,007 New	39,007 $19,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $1.44 $168 - $385	-268 Reduced 0.68%	39,312 $29,000
Q3 2021 Nov 12, 2021	BUY	$1.79 - $2.81 $70,848 - $111,219	39,580 New	39,580 $75,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $33.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.